Back to results
US 11,660,290 B2Granted
Affinity based drug release formulations
AssigneeMcMaster University
InventorsRyan Wylie, Vincent Huynh
Life of this patent
Estimating the term…
Abstract
The present application describes a two-step drug delivery formulation comprising a high affinity interaction between a drug conjugate and a compound, followed by introduction of a second compound with higher affinity to the drug conjugate to facilitate drug release. Delivery methods and specific interactions are also described.
Claims18
A drug release formulation comprising:
- a) a drug conjugate comprising a drug bound to a first member of an affinity binding pair;
- b) a second member of the affinity binding pair, wherein the drug conjugate reversibly binds to the second member of the affinity binding pair to form a complex;
- and
- c) a competitive binding compound that disrupts the binding between the drug conjugate and the second member of the affinity binding pair to result in drug release,
- wherein at least one of the first and second members of the affinity binding pair are bound to or encapsulated in a supporting matrix, and
- the competitive binding compound is comprised in the supporting matrix in a form selected from insoluble pellets and insoluble particles, and
- wherein the first member of the affinity binding pair is a protein with a binding affinity for biotin selected from streptavidin and a streptavidin derivative, the second member of the affinity binding pair is selected from desthiobiotin and a desthiobiotin derivative, and the competitive binding compound is selected from biotin and a biotin derivative, or
- the first member of the affinity binding pair is selected from desthiobiotin and a desthiobiotin derivative, the second member of the affinity binding pair is a protein with a binding affinity for biotin selected from streptavidin and a streptavidin derivative, and the competitive binding compound is selected from biotin and a biotin derivative.
5 more elements
A kit for drug release comprising
- a) a drug conjugate comprising a drug bound to a first member of an affinity binding pair;
- b) a second member of the affinity binding pair, wherein the drug conjugate reversibly binds to the second member of the affinity binding pair to form a complex;
- and
- c) a competitive binding compound that disrupts the binding between the drug conjugate and the second member of the affinity binding pair to result in drug release,
- wherein at least one of the first and second members of the affinity binding pair are bound to or encapsulated in a supporting matrix, and
- the competitive binding compound is comprised in the supporting matrix in a form selected from insoluble pellets and insoluble particles, and
- wherein the first member of the affinity binding pair is a protein with a binding affinity for biotin selected from streptavidin and a streptavidin derivative, the second member of the affinity binding pair is selected from desthiobiotin and a desthiobiotin derivative, and the competitive binding compound is selected from biotin and a biotin derivative, or
- the first member of the affinity binding pair is selected from desthiobiotin and a desthiobiotin derivative, the second member of the affinity binding pair is a protein with a binding affinity for biotin selected from streptavidin and a streptavidin derivative, and the competitive binding compound is selected from biotin and a biotin derivative.
5 more elements
Dependencies are inferred from the claim text.